---
title: "cochrane corticosteroids asthma"
year: 2023
month: 08
journal: "American Family Physician"
volume: "108"
issue: "08"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-08-cochrane-corticosteroids-asthma.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# cochrane corticosteroids asthma

                                          Cochrane for Clinicians
                                                   Putting Evidence Into Practice

Inspiratory Muscle Training for Chronic                                              This Cochrane review included 55 randomized controlled
Obstructive Pulmonary Disease                                                     trials (RCTs) and 2,467 patients.1 The studies were divided
Stephanie Algenio Anciro, MD, and Anna Milliren, DO                               into two arms:​pulmonary rehabilitation with inspira-
​David Grant Medical Center Family Medicine Residency                             tory muscle training vs. pulmonary rehabilitation alone
Program, Travis Air Force Base, California                                        (22 RCTs;​1,446 participants) and inspiratory muscle train-
                                                                                  ing vs. control or sham (37 RCTs;​1,021 participants). The
Author disclosure:​No relevant financial relationships.
                                                                                  studies addressed pulmonary rehabilitation and inspiratory
                                                                                  muscle training for interventions in COPD management.
Clinical Question                                                                 Participants were 44 years and older with stable COPD as
Is inspiratory muscle training alone or in combination                            diagnosed by the Global Initiative for Chronic Obstructive
with pulmonary rehabilitation effective for the treatment of                      Lung Disease criteria.
chronic obstructive pulmonary disease (COPD)?                                        Validated assessment tools were used to determine the
                                                                                  effects on three primary outcomes:​dyspnea, functional exer-
Evidence-Based Answer                                                             cise capacity, and health-related quality of life. With these
Inspiratory muscle training improves symptoms, phys-                              continuous data, the mean difference (MD) was used to ana-
ical fitness, and quality of life in patients with COPD.                          lyze the size of the treatment effect: 0.2 represented a small
When combined with pulmonary rehabilitation, inspi-                               effect,​0.5 was a medium effect,​and 0.8 was a large effect. The
ratory muscle training makes no difference compared                               tools used in the analysis for dyspnea were the Borg scale,
with pulmonary rehabilitation alone.1 (Strength of Rec-                           the modified Medical Research Council dyspnea scale and
ommendation:​B, inconsistent or limited-quality patient-                          the Baseline Dyspnea Index, and Transition Dyspnea Index.
oriented evidence.)                                                               The measure for functional exercise capacity was the six-
                                                                                  minute walk test, and the clinically significant measure for
Practice Pointers                                                                 health-related quality of life was the COPD Assessment Test.
Primary care physicians treat approximately 80% of patients                       The authors assessed the risk of bias in the included studies.
with COPD in the United States.2 Pulmonary rehabilitation                         Adverse effects were not reported.
is an individualized, supervised program incorporating                               When comparing inspiratory muscle training plus pul-
physiotherapy, nutritional and psychosocial care, and limb                        monary rehabilitation to pulmonary rehabilitation alone,
training. The Global Initiative for Chronic Obstructive                           there was little to no difference in the scores of each of
Lung Disease guideline recommends pulmonary rehabili-                             the three primary outcomes. However, inspiratory muscle
tation because it improves symptoms, exercise capacity, and                       training alone improved dyspnea compared with control or
quality of life across all grades of COPD severity. Inspira-                      sham on the Baseline Dyspnea Index and Transition Dys-
tory muscle training uses targeted exercises and devices to                       pnea Index (MD = 2.98;​95% CI, 2.07 to 3.89;​eight RCTs;​
increase the strength and endurance of the diaphragm and                          238 participants;​very low-certainty evidence). Patients
intercostal muscles because weakness of inspiratory muscles                       treated with inspiratory muscle training also demonstrated
is associated with dyspnea and respiratory failure in COPD.3                      improvement in functional exercise capacity compared with
Inspiratory muscle training is not typically included in pul-                     control or sham, with an increase of 35.71 meters (95% CI,
monary rehabilitation. The authors of the Cochrane review                         25.68 to 45.74;​ 16 RCTs;​ 501 participants;​ moderate-
sought to determine if inspiratory muscle training alone or                       certainty evidence) on the six-minute walk test. Inspi-
in combination with pulmonary rehabilitation can improve                          ratory muscle training improved health-related quality
symptoms of COPD.                                                                 of life (MD = −2.97;​95% CI, −3.85 to −2.10;​two RCTs;​86
                                                                                  participants;​ moderate-certainty evidence) on the COPD
                                                                                  Assessment Test, where any decrease in the test score rep-
  These are summaries of reviews from the Cochrane Library.
                                                                                  resents a decrease in overall symptoms of COPD. The other
  This series is coordinated by Corey D. Fogleman, MD, assis-
                                                                                  assessments for health-related quality of life and inspiratory
  tant medical editor.
                                                                                  muscle strength found statistically significant improvement,
  A collection of Cochrane for Clinicians published in AFP is
  available at https://www.aafp.org/afp/cochrane.                                 but the clinical significance of these changes is questionable
  CME This clinical content conforms to AAFP criteria for CME.
                                                                                  because of the risk of bias.
  See CME Quiz on page 126.                                                          Limitations of the studies included heterogeneity in pul-
                                                                                  monary rehabilitation and inspiratory muscle training

136  American
Downloaded  from Family   Physician
                 the American  Family Physician website at www.aafp.org/afp.            © 2023 American AcademyVolume
                                                                                 Copyright
                                                                   www.aafp.org/afp                                     of Family108,
                                                                                                                                  Physicians.
                                                                                                                                      Number  For2theAugust
                                                                                                                                                 ◆   private, non-
                                                                                                                                                              2023
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                       COCHRANE FOR CLINICIANS


and the significant risk of bias within the included studies.                  of ICSs show no reduction in the need for further interven-
Sources of bias were a lack of allocation concealment and a                    tion with primarily systemic corticosteroids vs. patients
lack of blinding.                                                              treated with stable doses of ICSs. Similarly, increased doses
  There are no guidelines recommending inspiratory                             of ICSs do not reduce unscheduled visits to physicians,
muscle training in addition to pulmonary rehabilitation.                       acute care facilities, or emergency departments or hospital
This Cochrane review supports current respiratory society                      admissions compared with stable doses of ICSs.1 (Strength of
statements regarding pulmonary rehabilitation, which con-                      Recommendation:​B, inconsistent or limited-quality patient-
clude that “[inspiratory muscle training] used in isolation                    oriented evidence.)
does confer benefits across several outcome areas,” but “its
added benefit as an adjunct to exercise training in COPD is                    Practice Pointers
questionable.”4                                                                Asthma is a leading cause of morbidity and mortality related
The practice recommendations in this activity are available at                 to chronic respiratory disease;​it affects 272 million people
https://​w ww.cochrane.org/CD013778.                                           worldwide.2,3 Early recognition and management of asthma
The opinions and assertions expressed herein are those of the                  exacerbations are essential in reducing morbidity, mortal-
authors and are not to be construed as official or as reflecting               ity, and health care costs associated with asthma. Asthma
the views of the U.S. Air Force, the U.S. Department of Defense,               action plans, which are written, patient-initiated, home
or the U.S. government.                                                        management guidelines that describe maintenance therapy
References                                                                     and steps for treatment escalation during an exacerbation,
                                                                               decrease the severity and duration of asthma exacerba-
1. Ammous O, Feki W, Lotfi T, et al. Inspiratory muscle training, with or
   without concomitant pulmonary rehabilitation, for chronic obstruc-          tions.1 ICSs are a mainstay of asthma action plans, and the
   tive pulmonary disease (COPD). Cochrane Database Syst Rev. 2023;​(1):​      Global Initiative for Asthma (GINA) guideline recommends
   CD013778.
                                                                               increased ICS dosing during an asthma exacerbation.4
2. Pace WD, Brandt E, Carter VA, et al. COPD population in US primary
   care:​data from the Optimum Patient Care DARTNet Research Database             The authors of the Cochrane review sought to determine
   and the Advancing the Patient Experience in COPD Registry. Ann Fam          the safety and effectiveness of increased ICS dosing as part of
   Med. 2022;​20(4):​319-327.                                                  patient-initiated home management in children and adults
3. Caron MA, Debigaré R, Dekhuijzen PNR, et al. Diaphragm and skeletal
   muscle dysfunction in COPD. Rev Mal Respir. 2011;​28(10):​1 250-1264.
                                                                               with mild to moderate persistent asthma.1 Asthma exacer-
4. Spruit MA, Singh SJ, Garvey C, et al.;​ATS/ERS Task Force on Pulmo-         bations required systemic corticosteroids or unscheduled
   nary Rehabilitation. An official American Thoracic Society/European         medical attention, including unscheduled physician visits,
   Respiratory Society statement:​key concepts and advances in pulmo-
                                                                               urgent care and emergency department visits, and hospi-
   nary rehabilitation [published correction appears in Am J Respir Crit
   Care Med. 2014;​189(12):​1570]. Am J Respir Crit Care Med. 2013;​188(8):​   tal admissions. The review included nine double-blinded,
   e13-e64.                                                                    randomized controlled trials of participants with mild to
                                                                               moderate persistent asthma from North America, Europe,
                                                                               Australia, and New Zealand between 1998 and 2018;​five
Effectiveness of Inhaled Corticosteroids for Acute                             trials included patients 15 years and older (n = 1,247), and
Asthma Exacerbations                                                           four included children younger than 15 years (n = 676).1 The
Tyler Rogers, MD, MBA, FAAFP;​Gregory Altman, MD;​                             primary outcome was treatment failure, defined as patients
and Paige Williams, MD, Martin Army Community Hospital,                        requiring rescue systemic corticosteroids. Secondary out-
Fort Moore, Georgia                                                            comes included unscheduled physician visits, urgent care
                                                                               and emergency department visits, hospital admissions, and
Patient perspective by Helen Haskell
                                                                               exacerbation duration (i.e., time until symptom recovery,
Author disclosure:​No relevant financial relationships.                        lung function recovery, or return to baseline beta1 agonist
                                                                               use). Nonserious and serious adverse events, including hos-
Clinical Question                                                              pitalization, prolongation of hospitalization, disability, fatal-
Does patient-initiated home management of asthma exac-                         ity, or study withdrawal related to any adverse event, were
erbations with increased doses of inhaled corticosteroids                      considered secondary outcomes.1,5
(ICSs) reduce the need for further intervention compared                          Among children and adults with mild to moderate per-
with a daily maintenance dosage of an ICS among children                       sistent asthma, action plans that instructed patients to
and adults with mild to moderate persistent asthma?                            increase their ICS dose at the onset of worsening asthma
                                                                               symptoms did not reduce asthma exacerbation severity or
Evidence-Based Answer                                                          duration and, therefore, did not reduce the need for sys-
In this Cochrane review, patients with mild to moderate                        temic corticosteroids. Unscheduled physician visits, visits
persistent asthma and symptoms consistent with an acute                        to the emergency department, and hospitalizations were
asthma exacerbation who are treated with increased doses                       not reduced. Secondary outcomes, including serious and

August 2023 ◆ Volume 108, Number 2                             www.aafp.org/afp                               American Family Physician 137
                                               COCHRANE FOR CLINICIANS


nonserious adverse events associated with increased ICS            understood from short-acting beta agonists such as albuterol.4
dosing, could not be included or excluded due to a lack of         The many interactions and contraindications of the ICS/
clinical significance.1                                            formoterol combination are barely discussed in the GINA
   These conclusions are limited by biases notable within the      update;​however, they were the subject of U.S. Food and Drug
individual trials, including differences among studies about       Administration warnings until recently and are detailed on
the patient’s baseline ICS dose, how much the treatment            reliable patient information websites.7-9 So, what is a patient
dose of ICS increased, how adherent patients were to their         to think? Effectiveness matters, but so does risk. The lesson
asthma action plan before the trial, and what the patient’s        seems to be that untreated asthma and its available treat-
baseline asthma severity was.1 Such biases result in wide          ments both entail a relatively high degree of risk. Altogether, it
CIs that limit the statistical validity and make the quality of    seems wise to recognize that there is substantial scope for pro-
data presented less helpful. Of note, study populations were       fessional and patient judgment and preference in the treat-
limited to patients with mild to moderate persistent asthma;​      ment of asthma exacerbations.
therefore, conclusions cannot be extended to patients with         The practice recommendations in this activity are available at
more severe asthma.                                                https://​w ww.cochrane.org/CD007524.
   A notable 2018 nonblinded study, which was excluded             The opinions and assertions expressed herein are those of
from this Cochrane review, indicated that quadrupling              the authors and do not reflect the official policy or position
the ICS dose may reduce systemic corticosteroid use or an          of the U.S. Army, the U.S. Department of Defense, or the U.S.
unscheduled health care consultation for asthma over 12            government.
months (incidence rate ratio = 0.82;​95% CI, 0.70 to 0.96),        References
particularly among people with more severe asthma.6 This
                                                                    1. Kew KM, Flemyng E, Quon BS, et al. Increased versus stable doses of
review had several challenges, including the absence of a pla-         inhaled corticosteroids for exacerbations of chronic asthma in adults
cebo control group, recruitment of a population not taking             and children. Cochrane Database Syst Rev. 2022;​(9):​CD007524.
maintenance ICS, and a design that compared the relative           2. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional,
effectiveness of two dosages of ICS as maintenance therapy.           and national deaths, prevalence, disability-adjusted life years, and years
                                                                      lived with disability for chronic obstructive pulmonary disease and
Further research is necessary.                                        asthma, 1990-2015:​a systematic analysis for the Global Burden of Dis-
   Although the results of this Cochrane review suggest               ease Study 2015 [published correction appears in Lancet Respir Med.
the use of stable ICS dosing during an exacerbation among             2017;​5(10):​e30]. Lancet Respir Med. 2017;​5(9):​691-706.

patients with mild to moderate persistent asthma, the GINA         3. GBD Chronic Respiratory Disease Collaborators. Prevalence and attrib-
                                                                      utable health burden of chronic respiratory diseases, 1990-2017:​a sys-
guideline recommends increasing ICS use as part of patient-           tematic analysis for the Global Burden of Disease Study 2017. Lancet
initiated asthma action plans during an acute exacerbation.4          Respir Med. 2020;​8(6):​585-596.
The GINA authors note that “little benefit may be seen from        4. Global Initiative for Asthma. 2023 GINA main report, global strategy for
increasing maintenance doses of ICS when background                   asthma management and prevention. May 2023. Accessed June 27,
                                                                      2023. https://​ginasthma.org/2023-gina-main-report
adherence is high” but emphasize several studies that were
                                                                   5. Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes:​exacerba-
outside the scope of this Cochrane review to create their             tions. J Allergy Clin Immunol. 2012;​1 29(3 suppl):​S34-S48.
guidance. Family physicians should be prepared to discuss          6. McKeever T, Mortimer K, Bradshaw L, et al. Temporarily quadrupling the
the evidence in the updated GINA recommendations with                 dose of inhaled steroid to prevent asthma exacerbations:​FAST. Health
patients who have mild to moderate asthma.                            Technol Assess. 2018;​22(70):​1-82.
                                                                    7. U.S. Food and Drug Administration. FDA drug safety communication:​
                                                                       FDA review finds no significant increase in risk of serious asthma out-
Patient Perspective                                                    comes with long-acting beta agonists (LABAs) used in combination
For patients and parents of children with asthma, a change             with inhaled corticosteroids (ICS). January 22, 2018. Accessed June
in treatment can be unsettling. Especially because of the              29, 2023. https://​w ww.fda.gov/drugs/drug-safety-and-availability/fda-
                                                                       drug-safety-communication-fda-review-finds-no-significant-increase-
limitations noted by the Cochrane reviewers, it may be hard            risk-serious-asthma-outcomes
for patients to understand asthma recommendations and              8. Mayo Clinic. Drugs and supplements:​budesonide and formo-
findings clearly. Patients should be reminded that medi-              terol (inhalation route). June 1, 2023. Accessed ​   June 29, 2023.​
cal recommendations are not set in stone but continually              ht tps:// ​ w w w.mayoclinic.org/drugs-supplement s/budesonide -​
                                                                      and-​formoterol-​inhalation-route/before-using/drg-20068949
change and evolve.
                                                                   9. Drugs.com. Budesonide/formoterol interactions. Accessed June
   One reason for the change in the GINA guidelines is                29, 2023. ​   https://​w ww.drugs.com/drug-interactions/budesonide-
research indicating that there is a greater risk than previously      formoterol.html ■




138 American Family Physician                         www.aafp.org/afp                              Volume 108, Number 2 ◆ August 2023
